Edition:
United States

Protalix Biotherapeutics Inc (PLX)

PLX on American Stock Exchange

0.67USD
18 Nov 2017
Change (% chg)

$0.01 (+1.52%)
Prev Close
$0.66
Open
$0.66
Day's High
$0.69
Day's Low
$0.66
Volume
596,524
Avg. Vol
994,114
52-wk High
$1.51
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Protalix Biotherapeutics enters into partnership with Chiesi Farmaceutici
Wednesday, 18 Oct 2017 06:50am EDT 

Oct 18 (Reuters) - Protalix Biotherapeutics Inc ::Protalix Biotherapeutics enters into an exclusive ex-US partnership with Chiesi Farmaceutici for the development and commercialization of PRX-102 (pegunigalsidase alfa) for the treatment of fabry disease.Protalix - co grants chiesi ex-US rights to PRX-102, a chemically modified version of recombinant protein alpha-galactosidase-a protein​.Protalix Biotherapeutics Inc - ‍to receive $25 million upfront, an additional up to $25 million in development costs​.Protalix Biotherapeutics Inc - ‍Protalix to receive tiered royalties ranging from 15% to 35% on net sales as part of deal​.Protalix Biotherapeutics Inc - ‍to receive an additional up to $320 million in potential regulatory and commercial milestone payments​.Protalix Biotherapeutics - ‍under terms of agreement, Protalix has licensed prx-102 to chiesi for all markets outside of United States​.Protalix Biotherapeutics - co will continue to be manufacturer of PRX-102 for clinical development purposes & commercial purposes after marketing approvals​.  Full Article

Protalix Biotherapeutics qtrly loss per share from continuing operations $0.47 ​
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Protalix Biotherapeutics Inc ::Protalix Biotherapeutics reports 2017 second quarter results and provides corporate update.Qtrly ‍revenues $6.4 million versus $1.8 million; qtrly loss per share from continuing operations $0.47 ​.  Full Article

Protalix Biotherapeutics updates on Phase II clinical trial results for Alidornase Alfa
Wednesday, 7 Jun 2017 07:30am EDT 

June 7 (Reuters) - Protalix Biotherapeutics Inc ::Protalix biotherapeutics announces Phase II clinical trial results for Alidornase Alfa in cystic fibrosis presented at the 40th EUROPEAN cystic fibrosis society conference."Alidornase Alfa was well tolerated with no serious adverse events reported".Protalix Biotherapeutics Inc says clinical data demonstrate over 70% reduction in presence of pseudomonas.  Full Article

Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility
Thursday, 1 Jun 2017 07:30am EDT 

June 1 (Reuters) - Protalix Biotherapeutics Inc :Protalix Biotherapeutics announces FDA approval to operate its current facility as a multi-product facility.Protalix Biotherapeutics Inc - approval of SNDA allows co to convert its manufacturing facility in Carmiel, Israel, to a multi-product facility.Protalix Biotherapeutics Inc - supplemental new drug application submitted to U.S. Food and Drug Administration has been approved by FDA.Protalix Biotherapeutics expects conversion of the facility to multi-product facilitywill allow company to realize potentially significant operational savings.Protalix Biotherapeutics - "conversion of facilities did not entail substantial additional capital expenditures".  Full Article

Protalix Biotherapeutics says presentation of clinical trial results for alidornase alfa
Tuesday, 23 May 2017 07:30am EDT 

May 23 (Reuters) - Protalix Biotherapeutics Inc :Protalix Biotherapeutics announces presentation of Phase II clinical trial results for Alidornase Alfa in cystic fibrosis at the 40th European cystic fibrosis society conference.  Full Article

Protalix Biotherapeutics reports Q1 loss per share $0.07 excluding items
Wednesday, 10 May 2017 07:30am EDT 

May 10 (Reuters) - Protalix Biotherapeutics Inc : :Protalix Biotherapeutics reports 2017 first quarter results and provides corporate update.Q1 revenue $2.9 million versus $679,000.Protalix Biotherapeutics Inc qtrly research and development expenses were $4.6 million, compared to $6.0 million for same period in 2016.Protalix Biotherapeutics - on March 31, 2017 Co had $48.0 million of cash and cash equivalents, which is currently projected to fund operations into 2019.Q1 loss per share $0.07 excluding items.Q1 earnings per share view $-0.09, revenue view $2.6 million -- Thomson Reuters I/B/E/S.  Full Article

Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa
Wednesday, 12 Apr 2017 07:30am EDT 

Protalix Biotherapeutics Inc : Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis . Protalix Biotherapeutics Inc - sixteen patients were enrolled in study, all of whom completed study . Protalix Biotherapeutics Inc - Alidornase Alfa was well tolerated with no serious adverse events reported . Protalix Biotherapeutics - adverse events that occurred during study were mild and transient in nature for phase ii clinical trial of Alidornase Alfa .Protalix Biotherapeutics - in vitro study of air dnase showed significant inhibition of pseudomonas aeruginosa.  Full Article

Protalix Biotherapeutics reports 2016 full year results
Thursday, 16 Mar 2017 08:00am EDT 

Protalix Biotherapeutics Inc : Protalix Biotherapeutics reports 2016 full year results and provides corporate update . Protalix Biotherapeutics - in 2018, if generate positive interim results from pegunigalsidase phase II trial, sees begin filing process for approval with EMA . Protalix Biotherapeutics Inc - anticipate funds will be sufficient to fund our operations into 2019 .Protalix Biotherapeutics Inc - at December 31, 2016, Protalix had $63.3 million of cash and cash equivalents, compared to $76.4 million at December 31, 2015.  Full Article

Protalix Biotherapeutics says last patient enrolled in mid-stage trial
Thursday, 22 Dec 2016 07:30am EST 

Protalix Biotherapeutics Inc : Protalix Biotherapeutics - expects to report interim top-line results from study during first week of Jan 2017, and full results before end of Q1 of 2017 .Protalix Biotherapeutics announces last patient enrolled in the Air Dnase phase II clinical trial for cystic fibrosis.  Full Article

Protalix Biotherapeutics announces private placement of secured convertible notes due 2021
Thursday, 1 Dec 2016 04:44pm EST 

Protalix Biotherapeutics Inc : Protalix biotherapeutics announces private note exchanges and private placement of secured convertible notes due 2021 . Protalix biotherapeutics says entered into definitive exchange agreement to exchange $54.1 million of outstanding 4.50% senior convertible notes due 2018 . Protalix biotherapeutics inc says exchange agrrement for $40.2 million principal amount of newly issued 7.50% senior secured convertible notes due 2021 . Protalix biotherapeutics inc says exchange agrrement for approximately 23.8 million shares of common stock, $0.001 par value per share .Protalix biotherapeutics-entered into definitive note purchase agreement with commitments to issue, sell $22.5 million principal amount of notes due 2021.  Full Article